As national programs introduce new, generic ARVs they must plan how and when the new product will be phased-in to ensure smooth and sustained adoption of optimal formulations. Ministries of Health must decide 1) which patient groups will be eligible to initiate on the new product, 2) when each patient group will start, and 3) how the new product will be rolled out geographically (national, regional, facility, or pilot). This tool is designed to help national programs simulate scenarios for product phase-in and evaluate rollout plan options. The output of this tool can also help define scale up targets at national, regional or facility level.
Comments